 |
|
Cost-effectiveness of B-Type Natriuretic Peptide Testing in Patients With Acute Dyspnea
Christian Mueller, MD;
Kirsten Laule-Kilian, BSc;
Christian Schindler, PhD;
Theresia Klima, MD;
Barbara Frana, MD;
Daniel Rodriguez, MD;
André Scholer, PhD;
Michael Christ, MD;
André P. Perruchoud, MD
Arch Intern Med. 2006;166:1081-1087.
Background B-type natriuretic peptide (BNP) is a quantitative marker of heart failure that seems to be helpful in its diagnosis.
Methods We performed a prospective randomized study (B-Type Natriuretic Peptide for Acute Shortness of Breath Evaluation) including 452 patients who presented to the emergency department with acute dyspnea to estimate the long-term cost-effectiveness of BNP guidance. Participants were randomly assigned to a diagnostic strategy involving the measurement of BNP levels (n = 225) or assessment in a standard manner (n = 227). Nonparametric bootstrapping was used to estimate the distribution of incremental costs and effects on the cost-effectiveness plane during 180 days of follow-up.
Results Testing of BNP induced several important changes in management of dyspnea, including a reduction in the initial hospital admission rate, the use of intensive care, and total days in the hospital at 180 days (median, 10 days [interquartile range, 2-24 days] in the BNP group vs 14 days [interquartile range, 6-27 days] in the control group; P = .005). At 180 days, all-cause mortality was 20% in the BNP group and 23% in the control group (P = .42). Total treatment cost was significantly reduced in the BNP group ($7930 vs $10 503 in the control group; P = .004). Analysis of incremental 180-day cost-effectiveness showed that BNP guidance resulted in lower mortality and lower cost in 80.6%, in higher mortality and lower cost in 19.3%, and in higher or lower mortality and higher cost in less than 0.1% each. Results were robust to changes in most variables but sensitive to changes in rehospitalization with BNP guidance.
Conclusion Testing of BNP is cost-effective in patients with acute dyspnea.
Author Affiliations: Department of Internal Medicine (Drs Mueller, Klima, Frana, Rodriguez, Christ, and Perruchoud and Ms Laule-Kilian), Institute of Social and Preventive Medicine (Dr Schindler), and Department of Laboratory Medicine (Dr Scholer), University Hospital, University of Basel, Basel, Switzerland.
RELATED LETTERS
Utility of B-Type Natriuretic Peptide Testing in the Emergency Department
Giorgio Costantino, Anna Maria Rusconi, Giovanni Casazza, and Nicola Montano
Arch Intern Med. 2006;166(20):2287.
EXTRACT
| FULL TEXT
Utility of B-Type Natriuretic Peptide Testing in the Emergency Department—Reply
Christian Mueller, Kirsten Laule-Kilian, Michael Christ, and André P. Perruchoud
Arch Intern Med. 2006;166(20):2288.
EXTRACT
| FULL TEXT
RELATED ARTICLES
The Value of BNP Testing
Mark Hlatky and Paul Heidenreich
Arch Intern Med. 2006;166(10):1063-1064.
EXTRACT
| FULL TEXT
Accuracy of B-Type Natriuretic Peptide Tests to Exclude Congestive Heart Failure: Systematic Review of Test Accuracy Studies
Markus Battaglia, Daniel Pewsner, Peter Jüni, Matthias Egger, Heiner C. Bucher, and Lucas M. Bachmann
Arch Intern Med. 2006;166(10):1073-1080.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Clinical Uncertainty, Diagnostic Accuracy, and Outcomes in Emergency Department Patients Presenting With Dyspnea
Green et al.
Arch Intern Med 2008;168:741-748.
ABSTRACT
| FULL TEXT
Discriminating Between Cardiac and Pulmonary Dysfunction in the General Population With Dyspnea by Plasma Pro-B-Type Natriuretic Peptide
Mogelvang et al.
J Am Coll Cardiol 2007;50:1694-1701.
ABSTRACT
| FULL TEXT
Medical and Economic Long-term Effects of B-Type Natriuretic Peptide Testing in Patients with Acute Dyspnea
Breidthardt et al.
Clin. Chem. 2007;53:1415-1422.
ABSTRACT
| FULL TEXT
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Utilization of Cardiac Biomarker Testing in Heart Failure
Wilson Tang et al.
Circulation 2007;116:e99-e109.
FULL TEXT
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology
Authors/Task Force Members et al.
Eur Heart J 2007;28:1598-1660.
FULL TEXT
Can We IMPROVE-CHF Management By Measuring Natriuretic Peptides?
Greenberg
Circulation 2007;115:3045-3047.
FULL TEXT
N-Terminal Pro-B-Type Natriuretic Peptide Testing Improves the Management of Patients With Suspected Acute Heart Failure: Primary Results of the Canadian Prospective Randomized Multicenter IMPROVE-CHF Study
Moe et al.
Circulation 2007;115:3103-3110.
ABSTRACT
| FULL TEXT
B type natriuretic peptide testing was more cost effective than conventional diagnosis in patients with acute dyspnoea
Shetty and Garber
Evid. Based Med. 2007;12:28-28.
FULL TEXT
Utility of B-Type Natriuretic Peptide Testing in the Emergency Department--Reply
Mueller et al.
Arch Intern Med 2006;166:2288-2288.
FULL TEXT
Utility of B-type natriuretic Peptide testing in the emergency department.
Costantino et al.
Arch Intern Med 2006;166:2287-2287.
FULL TEXT
BNP Testing: A Mixed Blessing
JWatch Emergency Med. 2006;2006:4-4.
FULL TEXT
BNP Testing for Acute Dyspnea: Is It Cost-Effective?
Journal Watch Cardiology 2006;2006:6-6.
FULL TEXT
The Value of BNP Testing.
Hlatky and Heidenreich
Arch Intern Med 2006;166:1063-1064.
FULL TEXT
|
